Description

The Guardian Panel focuses specifically on brain health and cognitive function, utilizing cutting-edge biomarkers to assess neurological health and identify early signs of cognitive decline.

This panel includes genetic risk assessment (ApoE genotype), advanced protein markers for Alzheimer’s disease (pTau-217, Beta-Amyloid), and glial fibrillary acidic protein (GFAP) for neuroinflammation assessment.

Biomarkers Included (4):

• ApoE Genotype – Genetic risk assessment
• pTau-217 – Advanced Alzheimer’s protein marker
• Beta-Amyloid 42/40 Ratio – Alzheimer’s disease indicator
• GFAP (Glial Fibrillary Acidic Protein) – Neuroinflammation assessment

Premium Membership add-on. Collection: Specialized blood draw. Frequency: Annually.